Similarly, a randomized phase II trial of seribantumab in combination with erlotinib in patients with EGFR wild-NSCLC demonstrated progression-free survival benefits in patients with detectable HRG mRNA in the tumor [152]. Here, EGFR is linked to neoplasm.